Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Kathleen E. DelGiorno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5749-8394; OpenAlex author ID A5078093187; NIH RePORTER profile ID 10626873. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
1
Labs led
1
Collaborators
56
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper, 1 grant

Papers 12

  1. Oncogenic KRAS-MAPK signaling sustains a CD73 dependent therapeutic vulnerability in pancreatic cancer Co-author DOI 10.64898/2026.10.20.760559↗
  2. Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer. Co-author DOI 10.1016/j.devcel.2024.12.003↗
  3. Targeting CREB remodels the immune microenvironment to enhance immunotherapy responses in pancreatic cancer Co-author DOI 10.64898/2025.12.04.691935↗
  4. Editorial: Emerging anti-cancer compounds and immunomodulators for pancreatic cancer treatment. Co-author DOI 10.3389/fonc.2024.1411836↗
  5. Bone Morphogenetic Protein (BMP) signaling upregulates expression of ID1 and ID3 in pancreatitis and pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2023.09.01.555987↗
  6. CD73 Is a Critical Immune Checkpoint in a Molecular Subtype of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-0268↗
  7. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
  8. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-019-1130-6↗
  9. Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy. First author DOI 10.1371/journal.pone.0189051↗
  10. Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase. First author DOI 10.1016/j.bpj.2016.03.040↗
  11. Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1053/j.gastro.2016.03.040↗
  12. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cell.2015.04.048↗

Grants 1

  1. Tuft cells resolve pancreatic injury through a Type 2 Immune circuit R01DK145538↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer M. Bailey · 2 shared papers, 2024–2026 · strength 0.62
  2. Stephen H Safe · 1 shared paper, 2024 · strength 0.36
  3. Urvinder Kaur Sardarni · 1 shared paper, 2026 · strength 0.26
  4. Khadija Shahab Turabi · 1 shared paper, 2026 · strength 0.26
  5. Marina Pasca di Magliano · 1 shared paper, 2026 · strength 0.26
  6. Thomas B. McFall · 1 shared paper, 2026 · strength 0.26
  7. Nina G. Steele · 1 shared paper, 2025 · strength 0.21
  8. Daniel James Salas-Escabillas · 1 shared paper, 2025 · strength 0.21
  9. Megan T. Hoffman · 1 shared paper, 2025 · strength 0.21
  10. Simone Benitz · 1 shared paper, 2025 · strength 0.21
  11. Rosalie C. Sears · 1 shared paper, 2025 · strength 0.21
  12. Brittany L. Allen-Petersen · 1 shared paper, 2025 · strength 0.21
  13. Howard C. Crawford · 1 shared paper, 2025 · strength 0.21
  14. Geoffrey Myles Wahl · 3 shared papers, 2017–2021 · strength 0.20
  15. Maya Ridinger-Saison · 3 shared papers, 2017–2021 · strength 0.20
  16. Andrew M. Lowy · 3 shared papers, 2017–2021 · strength 0.20
  17. Ronald M. Evans · 3 shared papers, 2017–2021 · strength 0.20
  18. H. Carlo Maurer · 1 shared paper, 2023 · strength 0.19
  19. Megha Raghunathan · 1 shared paper, 2023 · strength 0.19
  20. Pamela Itkin‐Ansari · 1 shared paper, 2023 · strength 0.19
  21. Sunil R. Hingorani · 3 shared papers, 2015–2016 · strength 0.19
  22. Oliver Gene McDonald · 1 shared paper, 2025 · strength 0.19
  23. Austin R. Dosch · 1 shared paper, 2025 · strength 0.19
  24. Vineet Kumar Gupta · 1 shared paper, 2025 · strength 0.19
  25. Jashodeep Datta · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.